0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
599 Ansichten1 Seite
This document discusses Biopure, a biopharmaceutical company developing two blood substitute products - Oxyglobin for veterinary use and Hemopure for human use. Oxyglobin recently received FDA approval, while Hemopure is still two years away from approval. The CEO is deciding whether to launch Oxyglobin now or wait for Hemopure approval. While some argue an early launch could hurt Hemopure's pricing, the VP of Veterinary Products believes Oxyglobin's revenue and experience would help Hemopure's launch. The author agrees, calculating Oxyglobin's veterinary market potential at $53 million based on 1995 blood demand data.
This document discusses Biopure, a biopharmaceutical company developing two blood substitute products - Oxyglobin for veterinary use and Hemopure for human use. Oxyglobin recently received FDA approval, while Hemopure is still two years away from approval. The CEO is deciding whether to launch Oxyglobin now or wait for Hemopure approval. While some argue an early launch could hurt Hemopure's pricing, the VP of Veterinary Products believes Oxyglobin's revenue and experience would help Hemopure's launch. The author agrees, calculating Oxyglobin's veterinary market potential at $53 million based on 1995 blood demand data.
This document discusses Biopure, a biopharmaceutical company developing two blood substitute products - Oxyglobin for veterinary use and Hemopure for human use. Oxyglobin recently received FDA approval, while Hemopure is still two years away from approval. The CEO is deciding whether to launch Oxyglobin now or wait for Hemopure approval. While some argue an early launch could hurt Hemopure's pricing, the VP of Veterinary Products believes Oxyglobin's revenue and experience would help Hemopure's launch. The author agrees, calculating Oxyglobin's veterinary market potential at $53 million based on 1995 blood demand data.
Biopure is a biopharmaceutical company that is trying to market two new blood
substitute products called Oxyglobin and Hemopure. The former is for use in animals and the latter is for use in humans. For animal use, Oxyglobin recently received FDAs final approval for commercial release. On the other hand, Hemopure, for use in human, is still two years away from FDA approval. Biopure CEO is trying to decide whether to launch Oxyglobin for veterinary market right away or to wait until Hemopure is approved by FDA and is released to human market first. Ted Jacobs, Biopure VP of Human Clinical Trials, contends that launching Oxyglobin at this moment could negatively impact the launch of Hemopure when it is finally approved in two years. He believes that the launch of Oxyglobin at the price point around $150 could create an unrealistic price expectation for Hemopure which could be priced around $800 per unit, and thus impact the sale. However, Andy Wright, VP of Veterinary Products, argues against Teds idea of holding off the sale of Oxyglobin. He points out that benefits of launching Oxyglobin at this moment outweigh the risks involved. He believes the revenue and product launch experience of Oxyglobin can ultimately help the launch of Hemopure. I agree with Andy Wrights reasoning to launch Oxyglobin as early as possible. While Oxyglobin could be priced around $150 based on animal market supply and demand, it does not necessarily mean Hemopures price cannot be priced five times more. Since the estimate price of $800 for Hemopure is based on market supply and demand, it should not come as a shock when it is finally released to the human blood substitute market. Moreover, according to the case study, there is no other competitor making blood substitute for animal market. It is a great opportunity for Biopure to enter the Veterinary market at this time. At worst case scenario, if Oxyglobin fails to succeed in the market, Biopure can at least learn from its mistakes with their first launch ever. To support my reasoning behind early launch of Oxyglobin, I will calculate Market Potentials for Veterinary market based on Bulidup model. Based on 1995 Veterinary blood demand data from the case, Calculation based Biopure case studys Veterinary blood demand data in 1995:
15,000 practices: 95% primary care and 5% emergency.
Average 17 units of blood by each primary care: Total units of blood-A = 0.95*15,000*17= 242,250
Average 150 units of blood by each emergency care:
Total units of blood-B = 0.05*15,000*150= 112,500
Market Potential= (242,250+112,500) * $150 per unit = $ 53,212,500 (53 millions) in